Mode
Text Size
Log in / Sign up
Phase 4 N=16 Treatment

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

Type 1 Diabetes Mellitus

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days — 136.4; 133.4; 113.5; 98.6 mg/dL

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
insulin glulisine (Drug); insulin aspart (Drug)
Age
Pediatric · 4+ yrs
Sex
All
Sponsor
Corewell Health West
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days
136.4; 133.4; 113.5; 98.6; 5.5; 4.4
SECONDARY
Occurrence of Hypoglycemia;
8; 9; 19; 26

Summary

To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.

Eligibility Criteria

Inclusion Criteria

  • current patient in the Helen DeVos Children's Hospital Diabetes Clinic;
  • ages 4-11 years;
  • prepubertal (Tanner Stage I);
  • diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or presenting at time of diagnosis with positive serum or urine ketones and requiring insulin since diagnosis;
  • at least six months from date of diagnosis of type 1 diabetes mellitus;
  • TSH within reference range and negative transglutaminase IgA antibodies within nine months of study start;
  • HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and willing to provide written informed consent prior to enrollment;
  • at time of study start, current insulin regimen includes multiple daily injections with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the pre-meal rapid acting insulin

Exclusion Criteria

  • pubertal (Tanner stage 2 or greater);
  • concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving oral, injectable or inhaled steroids or immunosuppressant medications;
  • receiving stimulants for treatment of attention deficit disorder or attention deficit hyperactivity disorder;
  • intercurrent illnesses such as a fever > 101 degrees F, infection, or gastroenteritis;
  • use of any medication to treat diabetes other than those listed under in inclusion criteria;
  • potential for lack of compliance or any other issue which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00913497). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search